Table 5 Clinical characteristics of... | American Society of Hematology

Table 5

Clinical characteristics of patients still on treatment, nilotinib-dasatinib group

Patient no.	Age, y	Duration of imatinib, mo	Nilotinib			Dasatinib
Patient no.	Age, y	Duration of imatinib, mo	Duration of nilotinib, mo	Best response	Reason off	Bcr-abl mutation before therapy	Dose, mg	Percentage of Ph-before therapy	Best response	Response duration, mo
2	47	43	14	mCyR	Grade II thrombocytopenia	None	140 QD	100	mCyR	34+
3	59	61	18	PCyR	Loss CyR	G250E	50 BID	100	mCyR	30+
7	64	48	5.6	CHR	Loss CHR	H396R	70 BID	100	CCyR	41+
31	66	54	25	MMR	Transformation	A276G	50 BID	55	MMR	30+
32	22	41	11	MMR	Grade II gynecomastia	E459G	50 BID	0	CCyR	26+
33	38	73	8.4	MMR	Transformation	None	100 QD	0	MMR	23+

Patient no.	Age, y	Duration of imatinib, mo	Nilotinib			Dasatinib
Patient no.	Age, y	Duration of imatinib, mo	Duration of nilotinib, mo	Best response	Reason off	Bcr-abl mutation before therapy	Dose, mg	Percentage of Ph-before therapy	Best response	Response duration, mo
2	47	43	14	mCyR	Grade II thrombocytopenia	None	140 QD	100	mCyR	34+
3	59	61	18	PCyR	Loss CyR	G250E	50 BID	100	mCyR	30+
7	64	48	5.6	CHR	Loss CHR	H396R	70 BID	100	CCyR	41+
31	66	54	25	MMR	Transformation	A276G	50 BID	55	MMR	30+
32	22	41	11	MMR	Grade II gynecomastia	E459G	50 BID	0	CCyR	26+
33	38	73	8.4	MMR	Transformation	None	100 QD	0	MMR	23+

QD indicates once daily; and BID, twice daily.